A short piece on the effectiveness of Novo Nordisk's oral version of Wegovy. Only the headline is available, so tap through for the findings.
Recap by typeshit. Full story at ΕΜΥ.
EMY covers findings suggesting GLP-1 drugs such as Wegovy could lower the risk of certain cancers. Details on which cancers are in the full story.
Shah points to research published September 2 in which older mice given semaglutide lived longer, with effects he says went beyond blood sugar control.
The review weighs weight and metabolic benefits in people with IBD against early lab hints of anti-inflammatory effects, and looks at what observational studies show so far.
The obesity doctor takes on why some people see weaker results on GLP-1 medications. Short clip with few details given.
Shares fell about 41% in a month after a $500 million raise. Investors want details on the new SUNRISE oral trial, which follows phase 2 weight loss of up to 12.2% in 13 weeks.
Tuttle points to the FLOW trial's 24% relative risk cut in major kidney outcomes and lays out how guidelines add therapies one at a time.
Loading…